Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eculizumab in HELLP Syndrome

NCT04103489 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT04103489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04103489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eculizumab in HELLP Syndrome
Lead sponsor
Johns Hopkins University
Phase
Phase 1
Overall status
Completed
Start date
February 23, 2021
Completion date
September 4, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

complement abnormality, hellp syndrome (hellp), third trimester, maternal injury, morbidity;newborn, preeclampsia severe